In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnin...
TRULICITY ® is indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiov...
The recommended starting dosage of TRULICITY is 0.75 mg injected subcutaneously once weekly. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ) and Adverse Reactions ( 6.1 )]. After 4 weeks, the dosage may be increased to 1.5 mg once weekly for additional glycemic control. If additional glycemic control is needed, increase the dosage in...
TRULICITY (dulaglutide) injection is a clear and colorless solution supplied in single-dose pens. TRULICITY is packaged in a cardboard outer carton containing 4 single-dose TRULICITY pens and is supplied as follows: Total Strength per Total Volume NDC 0.75 mg/0.5 mL NDC 0002-1433-80 1.5 mg/0.5 mL NDC 0002-1434-80 3 mg/0.5 mL NDC 0002-2236-80 4.5 mg/0.5 mL NDC 0002-3182-80 Store TRULICITY in the refrigerator at 36°...
www.fda.gov/medwatch
www.lilly.com/patents
www.TRULICITY.comwww.fda.gov/safesharpsdisposalwww.trulicity.comTRULICITY® is indicated:
Injection: TRULICITY is a clear and colorless solution available as:
TRULICITY is contraindicated in patients with:
In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure [see Nonclinical Toxicology (13.1)]. Glucagon-like peptide-1 (GLP-1) receptor agonists have induced thyroid C-cell adenomas and carcinomas in mice and rats at clinically relevant exposures. It is unknown whether TRULICITY will cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined.
One case of MTC was reported in a patient treated with TRULICITY in a clinical trial. This patient had pretreatment calcitonin levels approximately 8 times the upper limit of normal (ULN). An additional case of C-cell hyperplasia with elevated calcitonin levels following treatment was reported in the cardiovascular outcomes trial (REWIND). Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans.
TRULICITY is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2. Counsel patients regarding the potential risk for MTC with the use of TRULICITY and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness).
Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with TRULICITY. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.
Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including TRULICITY [see Adverse Reactions (6)].
After initiation of TRULICITY, observe patients carefully for signs and symptoms of acute pancreatitis which may include persistent or severe abdominal pain (sometimes radiating to the back) and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue TRULICITY and initiate appropriate management.
Patients receiving TRULICITY in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia [see Adverse Reactions (6.1) and Drug Interactions (7)].
The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
There have been postmarketing reports of serious hypersensitivity reactions including anaphylactic reactions and angioedema in patients treated with TRULICITY [see Adverse Reactions (6.2)]. If a hypersensitivity reaction occurs, discontinue TRULICITY; treat promptly per standard of care, and monitor until signs and symptoms resolve. TRULICITY is contraindicated in patients with a previous serious hypersensitivity reaction to dulaglutide or to any of the components of TRULICITY.
Anaphylaxis and angioedema have been reported with other GLP-1 receptor agonists. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to anaphylaxis with TRULICITY.
There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, including TRULICITY [see Adverse Reactions (6.2)]. The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea [see Adverse Reactions (6.1)]. Monitor renal function in patients reporting adverse reactions to TRULICITY that could lead to volume depletion, especially during dosage initiation and escalation of TRULICITY.
Use of TRULICITY has been associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions (6)]. In the pool of placebo-controlled trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving TRULICITY (0.75 mg 2.2%, 1.5 mg 4.3%) than placebo (1.4%). Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists.
TRULICITY is not recommended in patients with severe gastroparesis.
In a cardiovascular outcomes trial with a median follow up of 5.4 years involving patients with type 2 diabetes with established cardiovascular disease or multiple cardiovascular risk factors, diabetic retinopathy complications occurred in patients treated with TRULICITY 1.5 mg (1.9%) and placebo (1.5%). These events were prospectively ascertained as a secondary composite endpoint. The proportion of patients with diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline (TRULICITY 8.5%, placebo 6.2%) than among patients without a known history of diabetic retinopathy (TRULICITY 1%, placebo 1%).
Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In a cardiovascular outcomes trial with a median follow up of 5.4 years, cholelithiasis occurred at a rate of 0.62/100 patient-years in TRULICITY-treated patients and 0.56/100 patient-years in placebo-treated patients after adjusting for prior cholecystectomy. Serious events of acute cholecystitis were reported in 0.5% and 0.3% of patients on TRULICITY and placebo respectively. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.
TRULICITY delays gastric emptying [see Clinical Pharmacology (12.2)]. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations.
Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking TRULICITY, including whether modifying preoperative fasting recommendations or temporarily discontinuing TRULICITY could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking TRULICITY.
The following serious reactions are described below or elsewhere in the prescribing information:
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Adverse Reactions in the Clinical Trials in Adults with Type 2 Diabetes Mellitus
Pool of Adult Placebo-Controlled Trials for TRULICITY 0.75 mg and 1.5 mg Doses
The data in Table 1 are derived from a pool of placebo-controlled trials and include 1,670 adult patients with type 2 diabetes mellitus exposed to TRULICITY with a mean duration of exposure of 23.8 weeks [see Clinical Studies (14)]. The mean age of patients was 56 years, 1% were 75 years or older and 53% were male. The population was 69% White, 7% Black or African American, 13% Asian; 30% were of Hispanic or Latino ethnicity. At baseline, the population had diabetes for an average of 8 years, a mean HbA1c of 8.0%, and 2.5% of the population reported retinopathy. Baseline estimated renal function was normal or mildly impaired (eGFR ≥60 mL/min/1.73 m2) in 96%.
Table 1 shows adverse reactions, excluding hypoglycemia, occurring in ≥5% of TRULICITY treated adult patients and more commonly than placebo in a pool of placebo-controlled trials.
| |||
| |||
| |||
| |||
| |||
| Adverse Reaction | Placebo (N=568) % | TRULICITY 0.75 mg (N=836) % | TRULICITY 1.5 mg (N=834) % |
| Nausea | 5.3 | 12.4 | 21.1 |
| Diarrheaa | 6.7 | 8.9 | 12.6 |
| Vomitingb | 2.3 | 6.0 | 12.7 |
| Abdominal Painc | 4.9 | 6.5 | 9.4 |
| Decreased Appetite | 1.6 | 4.9 | 8.6 |
| Dyspepsia | 2.3 | 4.1 | 5.8 |
| Fatigued | 2.6 | 4.2 | 5.6 |
Gastrointestinal Adverse Reactions
In the pool of placebo-controlled trials, gastrointestinal (GI) adverse reactions occurred more frequently among patients who received TRULICITY compared to patients who received placebo (placebo 21%, 0.75 mg 32%, 1.5 mg 41%). A higher percentage of patients who received TRULICITY 0.75 mg (1.3%) and TRULICITY 1.5 mg (3.5%) discontinued treatment due to GI adverse reactions than patients who received placebo (0.2%). Investigators graded the severity of GI adverse reactions that occurred in those treated with 0.75 mg and 1.5 mg of TRULICITY as “mild” in 58% and 48% of cases, respectively, “moderate” in 35% and 42% of cases, respectively, or “severe” in 7% and 11% of cases, respectively.
The following GI adverse reactions were reported more frequently in TRULICITY-treated patients than placebo -treated patients (frequencies listed, respectively, as: placebo; 0.75 mg; 1.5 mg): constipation (0.7%, 3.9%, 3.7%), flatulence (1.4%, 1.4%, 3.4%), abdominal distension (0.7%, 2.9%, 2.3%), gastroesophageal reflux disease (0.5%, 1.7%, 2.0%), and eructation (0.2%, 0.6%, 1.6%).
Adult Dose Ranging Trial for TRULICITY 3 mg and 4.5 mg Doses
Table 2 shows adverse reactions occurring ≥5% in any of the treatment groups through 36 weeks in a clinical trial with 1842 adult patients with type 2 diabetes mellitus treated with TRULICITY 1.5 mg, 3 mg, or 4.5 mg subcutaneously once weekly as an add-on to metformin [see Clinical Studies (14.3)]. The adverse reaction profile is consistent with previous clinical trials in adults.
| |||
| Adverse Reaction | TRULICITY 1.5 mg (N=612) % | TRULICITY 3 mg (N=616) % | TRULICITY 4.5 mg (N=614) % |
| Nausea | 13.4 | 15.6 | 16.4 |
| Diarrhea | 7.0 | 11.4 | 10.7 |
| Vomiting | 5.6 | 8.3 | 9.3 |
| Dyspepsia | 2.8 | 5.0 | 2.6 |
Other Adverse Reactions in Adults
Hypoglycemia
Table 3 summarizes the incidence of hypoglycemia in the placebo-controlled clinical studies in adult patients with type 2 diabetes mellitus: episodes with a glucose level <54 mg/dL with or without symptoms, and severe hypoglycemia, defined as an episode requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.
| Placebo | TRULICITY 0.75 mg | TRULICITY 1.5 mg | |
| Add-on to Metformin | |||
| (26 weeks) | N=177 | N=302 | N=304 |
| Hypoglycemia with a glucose level <54 mg/dL | 0 | 0.3 | 0.7 |
| Severe hypoglycemia | 0 | 0 | 0 |
| Add-on to Metformin + Pioglitazone | |||
| (26 weeks) | N=141 | N=280 | N=279 |
| Hypoglycemia with a glucose level <54 mg/dL | 1.4 | 2.1 | 0 |
| Severe hypoglycemia | 0 | 0 | 0 |
| Add-on to Glimepiride | |||
| (24 weeks) | N=60 | - | N=239 |
| Hypoglycemia with a glucose level <54 mg/dL | 0 | - | 3.3 |
| Severe hypoglycemia | 0 | - | 0 |
| In Combination with Insulin Glargine ± Metformin | |||
| (28 weeks) | N=150 | - | N=150 |
| Hypoglycemia with a glucose level <54 mg/dL | 9.3 | - | 14.7 |
| Severe hypoglycemia | 0 | - | 0.7 |
| Add-on to SGLT2i ± Metformin | |||
| (24 weeks) | N=140 | N=141 | N=142 |
| Hypoglycemia with a glucose level <54 mg/dL | 0.7 | 0.7 | 0.7 |
| Severe hypoglycemia | 0 | 0.7 | 0 |
Hypoglycemia was more frequent when TRULICITY was used in combination with a sulfonylurea or insulin than when used with non-secretagogues. In a 78-week adult clinical trial, hypoglycemia (glucose level <54 mg/dL) occurred in 20% and 21% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with a sulfonylurea. Severe hypoglycemia occurred in 0% and 0.7% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with a sulfonylurea. In a 52-week adult clinical trial, hypoglycemia (glucose level <54 mg/dL) occurred in 77% and 69% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with prandial insulin. Severe hypoglycemia occurred in 2.7% and 3.4% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with prandial insulin. Refer to Table 3 for the incidence of hypoglycemia in patients treated in combination with basal insulin glargine.
In the clinical trial with adult patients on TRULICITY 1.5 mg, TRULICITY 3 mg, or TRULICITY 4.5 mg once weekly, as add-on to metformin, incidences of hypoglycemia (glucose level <54 mg/dL) through 36 weeks were 1.1%, 0.3%, and 1.1%, respectively, and incidences of severe hypoglycemia were 0.2%, 0%, and 0.2%, respectively.
Cholelithiasis and Cholecystitis
In a cardiovascular outcomes trial in adult patients with type 2 diabetes mellitus and established cardiovascular (CV) disease or multiple cardiovascular risk factors with a median follow up of 5.4 years [see Clinical Studies 14.5], cholelithiasis occurred at a rate of 0.62/100 patient-years in TRULICITY-treated patients and 0.56/100 patient-years in placebo-treated patients after adjusting for prior cholecystectomy. Serious events of acute cholecystitis were reported in 0.5% and 0.3% of patients on TRULICITY and placebo respectively.
Heart Rate Increase and Tachycardia-Related Adverse Reactions
In adult patients, TRULICITY 0.75 mg and 1.5 mg resulted in a mean increase in heart rate (HR) of 2-4 beats per minute (bpm).
Adverse reactions of sinus tachycardia were reported more frequently in patients exposed to TRULICITY. Sinus tachycardia was reported in 3.0%, 2.8%, and 5.6% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively. Persistence of sinus tachycardia (reported at more than 2 visits) was reported in 0.2%, 0.4% and 1.6% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively. Episodes of sinus tachycardia, associated with a concomitant increase from baseline in heart rate of ≥15 beats per minute, were reported in 0.7%, 1.3% and 2.2% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively.
Hypersensitivity
Systemic hypersensitivity adverse reactions, sometimes severe (e.g., severe urticaria, systemic rash, facial edema, lip swelling), occurred in 0.5% of adult patients on TRULICITY in clinical studies.
Injection-site Reactions
In the placebo-controlled studies in adults, injection-site reactions (e.g., injection-site rash, erythema) were reported in 0.5% of TRULICITY-treated patients and in 0.0% of placebo-treated patients.
PR Interval Prolongation and Adverse Reactions of First-Degree Atrioventricular (AV) Block
A mean increase from baseline in PR interval of 2-3 milliseconds was observed in TRULICITY-treated adult patients in contrast to a mean decrease of 0.9 milliseconds in placebo-treated patients. The adverse reaction of first-degree AV block occurred more frequently in patients treated with TRULICITY than placebo (0.9%, 1.7% and 2.3% for placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively). On electrocardiograms, a PR interval increase to at least 220 milliseconds was observed in 0.7%, 2.5% and 3.2% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively.
Acute Pancreatitis
In a pooled analysis from the original registration studies, 12 (3.4 cases per 1,000 patient years) pancreatitis-related adverse reactions were reported in patients exposed to TRULICITY versus 3 in non-incretin comparators (2.7 cases per 1000 patient years). An analysis of adjudicated events revealed 5 cases of confirmed pancreatitis in patients exposed to TRULICITY (1.4 cases per 1,000 patient years) versus 1 case in non-incretin comparators (0.88 cases per 1,000 patient years).
Based on an analysis of adjudicated events in a clinical trial evaluating Trulicity 1.5 mg, 3 mg, or 4.5 mg once weekly, pancreatitis occurred in 1 patient exposed to TRULICITY 1.5 mg (0.2%), in 2 patients exposed to TRULICITY 3 mg (0.3%), and 3 patients exposed to TRULICITY 4.5 mg (0.5%).
Amylase and Lipase Increase
Adult patients exposed to TRULICITY had mean increases from baseline in lipase and/or pancreatic amylase of 14% to 20%, while placebo-treated patients had mean increases of up to 3%.
Adverse Reactions in the Clinical Trial of Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus
TRULICITY was administered to 150 pediatric patients 10 years of age and older with type 2 diabetes mellitus for a mean duration of 41.3 weeks [see Clinical Studies (14.6)]. The mean age was 14.5 years and 71% of patients were female. Overall, 55% were White, 15% were Black or African American, 12% were Asian, 10% were American Indian or Alaska Native, 5% were other races, and 3% had unknown race. Additionally, 55% were Hispanic or Latino, 42% were not Hispanic or Latino, and 3% had unknown ethnicity. At baseline, the mean duration of type 2 diabetes mellitus was 2 years, mean HbA1c was 8.1%, mean weight was 90.5 kg and mean BMI was 34.1 kg/m2.
The safety profile in pediatric patients treated with TRULICITY 0.75 mg and 1.5 mg subcutaneously once-weekly was consistent with that described above for adult patients with type 2 diabetes mellitus with the exception of injection site reactions. In pediatric patients, the incidence of injection site reactions was 3.9% (2 patients) in the TRULICITY 0.75 mg group, 3.8% (2 patients) in the TRULICITY 1.5 mg group, and 2.0% (1 patient) in the placebo group.
The following additional adverse reactions have been reported during post-approval use of TRULICITY. Because these events are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
TRULICITY delays gastric emptying and thus has the potential to reduce the rate of absorption of concomitantly administered oral medications. The delay in gastric emptying is dose-dependent but is attenuated with the recommended dose escalation to higher doses of TRULICITY [see Dosage and Administration (2.1)]. The delay is largest after the first dose and diminishes with subsequent doses. In clinical pharmacology studies, TRULICITY 1.5 mg did not affect the absorption of the tested orally administered medications to a clinically relevant degree [see Clinical Pharmacology (12.3)]. There is limited experience with the use of concomitant medications in clinical trials with TRULICITY doses of 3 mg and 4.5 mg.
Monitor drug levels of oral medications with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with TRULICITY.
Risk Summary
Limited data with TRULICITY in pregnant women are not sufficient to determine a drug-associated risk for major birth defects and miscarriage. There are clinical considerations regarding the risks of poorly controlled diabetes in pregnancy [see Clinical Considerations]. Based on animal reproduction studies, there may be risks to the fetus from exposure to dulaglutide during pregnancy. TRULICITY should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
In pregnant rats administered dulaglutide during organogenesis, early embryonic deaths, fetal growth reductions, and fetal abnormalities occurred at systemic exposures at least 6-times human exposure at the maximum recommended human dose (MRHD) of 4.5 mg/week. In pregnant rabbits administered dulaglutide during organogenesis, major fetal abnormalities occurred at 5-times human exposure at the MRHD. Adverse embryo/fetal effects in animals occurred in association with decreased maternal weight and food consumption attributed to the pharmacology of dulaglutide [see Data].
The estimated background risk of major birth defects is 6–10% in women with pre-gestational diabetes with an HbA1c >7% and has been reported to be as high as 20–25% in women with an HbA1c >10%. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively.
Clinical Considerations
Disease-associated maternal and/or embryo/fetal risk
Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity.
Data
Animal Data
Pregnant rats given subcutaneous doses of 0.49, 1.63, or 4.89 mg/kg dulaglutide every 3 days during organogenesis had systemic exposures 2-, 6-, and 18-times human exposure at the maximum recommended human dose (MRHD) of 4.5 mg/week, respectively, based on plasma area under the time-concentration curve (AUC) comparison. Reduced fetal weights associated with decreased maternal food intake and decreased weight gain attributed to the pharmacology of dulaglutide were observed at ≥1.63 mg/kg. Irregular skeletal ossifications and increases in post-implantation loss also were observed at 4.89 mg/kg.
In pregnant rabbits given subcutaneous doses of 0.04, 0.12, or 0.41 mg/kg dulaglutide every 3 days during organogenesis, systemic exposures in pregnant rabbits were 0.5-, 2-, and 5-times human exposure at the MRHD, based on plasma AUC comparison. Fetal visceral malformation of lung lobular agenesis and skeletal malformations of the vertebrae and/or ribs were observed in conjunction with decreased maternal food intake and decreased weight gain attributed to the pharmacology of dulaglutide at 0.41 mg/kg.
In a prenatal-postnatal study in F0 maternal rats given subcutaneous doses of 0.2, 0.49, or 1.63 mg/kg every third day from implantation through lactation, systemic exposures in pregnant rats were 1-, 2-, and 7-times human exposure at the MRHD, based on plasma AUC comparison. F1 pups from F0 maternal rats given 1.63 mg/kg dulaglutide had statistically significantly lower mean body weight from birth through postnatal day 63 for males and postnatal day 84 for females. F1 offspring from F0 maternal rats receiving 1.63 mg/kg dulaglutide had decreased forelimb and hindlimb grip strength and males had delayed balano-preputial separation. Females had decreased startle response. These physical findings may relate to the decreased size of the offspring relative to controls as they appeared at early postnatal assessments but were not observed at a later assessment. F1 female offspring of the F0 maternal rats given 1.63 mg/kg of dulaglutide had a longer mean escape time and a higher mean number of errors relative to concurrent control during 1 of 2 trials in the memory evaluation portion of the Biel water maze. These findings occurred in conjunction with decreased F0 maternal food intake and decreased weight gain attributed to the pharmacologic activity at 1.63 mg/kg. The human relevance of these memory deficits in the F1 female rats is not known.
Risk Summary
There are no data on the presence of dulaglutide in human milk, the effects on the breastfed infant, or the effects on milk production. The presence of dulaglutide in milk of treated lactating animals was not determined. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for TRULICITY and any potential adverse effects on the breastfed infant from TRULICITY or from the underlying maternal condition.
The safety and effectiveness of TRULICITY as an adjunct to diet and exercise to improve glycemic control in pediatric patients 10 years of age and older with type 2 diabetes mellitus have been established. Use of TRULICITY for this indication is supported by a 26-week, multicenter, randomized, double-blind, parallel arm, placebo-controlled trial in 154 pediatric patients 10 years of age and older with type 2 diabetes mellitus [see Clinical Studies (14.6)].
TRULICITY-treated pediatric patients reported a higher incidence of injection site-related reactions compared to TRULICITY-treated adults [see Adverse Reactions (6.1)].
The safety and effectiveness of TRULICITY have not been established in pediatric patients less than 10 years of age.
In the adult glycemic control trials [see Clinical Studies (14.2, 14.3)], 620 (19%) of TRULICITY-treated patients were 65 years of age or older and 65 (2%) of TRULICITY-treated patients were 75 years of age or older at baseline. In the TRULICITY 1.5 mg treatment arm of the REWIND trial (cardiovascular outcomes trial in adults with type 2 diabetes mellitus and cardiovascular disease or multiple cardiovascular risk factors) [see Clinical Studies (14.5)], 2,619 (53%) patients were 65 years of age or older, and 484 (10%) patients were 75 years of age or older at baseline.
No overall differences in safety or effectiveness for TRULICITY have been observed between patients 65 years of age and older and younger adult patients.
TRULICITY has been studied in patients with varying degrees of renal function, including a dedicated clinical trial in patients with moderate to severe chronic kidney disease. No overall differences in safety or effectiveness were observed in these studies according to renal function [see Clinical Studies (14.2, 14.3, 14.4)].
In a clinical pharmacology study in patients with renal impairment, including end-stage renal disease (ESRD), no clinically relevant change in dulaglutide pharmacokinetics (PK) was observed. In the 52-week trial in patients with type 2 diabetes and moderate to severe renal impairment, the PK behavior of TRULICITY 0.75 mg and 1.5 mg once weekly was similar to that demonstrated in previous clinical studies [see Clinical Pharmacology (12.3)].
No dose adjustment is recommended in patients with renal impairment including end-stage renal disease (ESRD). Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions. Use TRULICITY with caution in patients with ESRD [see Warning and Precautions (5.5), Clinical Pharmacology (12.3)].
In a clinical pharmacology study in patients with varying degrees of hepatic impairment, no clinically relevant change in dulaglutide PK was observed [see Clinical Pharmacology (12.3)]. However, there is limited clinical experience in patients with mild, moderate, or severe hepatic impairment; therefore, use TRULICITY with caution in these patient populations.
Overdoses have been reported in clinical studies. Effects associated with these overdoses were primarily mild or moderate gastrointestinal events (e.g., nausea, vomiting) and non-severe hypoglycemia. In the event of overdose, consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations. Initiate appropriate supportive care (including frequent plasma glucose monitoring) according to the patient's clinical signs and symptoms.
Dulaglutide is a human GLP-1 receptor agonist. The molecule is a fusion protein that consists of 2 identical, disulfide-linked chains, each containing an N-terminal GLP-1 analog sequence covalently linked to the Fc portion of a modified human immunoglobulin G4 (IgG4) heavy chain by a small peptide linker and is produced using mammalian cell (Chinese hamster ovary) culture. The GLP-1 analog portion of dulaglutide is 90% homologous to native human GLP-1 (7-37). Structural modifications were introduced in the GLP-1 part of the molecule responsible for interaction with the enzyme dipeptidyl-peptidase-IV (DPP-4). Additional modifications were made in an area with a potential T-cell epitope and in the areas of the IgG4 Fc part of the molecule responsible for binding the high-affinity Fc receptors and half-antibody formation. The overall molecular weight of dulaglutide is approximately 63 kilodaltons.
TRULICITY (dulaglutide) injection is a clear, colorless, sterile, preservative-free solution for subcutaneous use. Each single-dose pen contains a 0.5 mL solution of 0.75 mg, 1.5 mg, 3 mg, or 4.5 mg of dulaglutide and the following excipients: citric acid anhydrous (0.07 mg), mannitol (23.2 mg), polysorbate 80 (0.10 mg for 0.75 mg and 1.5 mg; 0.125 mg for 3 mg and 4.5 mg), and trisodium citrate dihydrate (1.37 mg), in water for injection.
TRULICITY contains dulaglutide, which is a human GLP-1 receptor agonist with 90% amino acid sequence homology to endogenous human GLP-1 (7-37). Dulaglutide activates the GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase in pancreatic beta cells. Dulaglutide increases intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent insulin release. Dulaglutide also decreases glucagon secretion and slows gastric emptying.
TRULICITY lowers fasting glucose and reduces postprandial glucose (PPG) concentrations in patients with type 2 diabetes mellitus. The reduction in fasting and postprandial glucose can be observed after a single dose.
Fasting and Postprandial Glucose
In a clinical pharmacology study in patients with type 2 diabetes mellitus, treatment with once weekly TRULICITY resulted in a reduction of fasting and 2-hour PPG concentrations, and postprandial serum glucose incremental AUC, when compared to placebo (-25.6 mg/dL, -59.5 mg/dL, and -197 mg*h/dL, respectively); these effects were sustained after 6 weeks of dosing with the 1.5 mg dose.
First- and Second-Phase Insulin Secretion
Both first- and second-phase insulin secretion were increased in patients with type 2 diabetes treated with TRULICITY compared with placebo.
Insulin and Glucagon Secretion
TRULICITY stimulates glucose-dependent insulin secretion and reduces glucagon secretion. Treatment with TRULICITY 0.75 mg and 1.5 mg once weekly increased fasting insulin from baseline at Week 26 by 35.38 and 17.50 pmol/L, respectively, and C-peptide concentration by 0.09 and 0.07 nmol/L, respectively, in a monotherapy trial. In the same trial, fasting glucagon concentration was reduced by 1.71 and 2.05 pmol/L from baseline with TRULICITY 0.75 mg and 1.5 mg, respectively.
Gastric Motility
Dulaglutide causes a delay of gastric emptying. The delay in gastric emptying is dose-dependent but is attenuated with adequate dose escalation to higher doses of TRULICITY. The delay is largest after the first dose and diminishes with subsequent doses.
Cardiac Electrophysiology (QTc)
The effect of dulaglutide on cardiac repolarization was tested in a thorough QTc study. Dulaglutide did not produce QTc prolongation at doses of 4 and 7 mg. The maximum recommended dose is 4.5 mg once weekly.
The pharmacokinetics of dulaglutide is similar between healthy subjects and patients with type 2 diabetes mellitus. Following subcutaneous administration, the time to maximum plasma concentration of dulaglutide at steady state ranges from 24 to 72 hours, with a median of 48 hours. After reaching steady state, the accumulation ratio was approximately 1.56. Steady-state plasma dulaglutide concentrations were achieved between 2 and 4 weeks following once weekly administration. Site of subcutaneous administration (abdomen, upper arm, and thigh) had no statistically significant effect on the exposure to dulaglutide.
Absorption – The mean absolute bioavailability of dulaglutide following subcutaneous administration of single 0.75 mg and 1.5 mg doses was 65% and 47%, respectively. Absolute subcutaneous bioavailability for 3 mg and 4.5 mg doses were estimated to be similar to 1.5 mg although this has not been specifically studied. Dulaglutide concentrations increased approximately proportional to dose from 0.75 mg to 4.5 mg.
Distribution – Apparent population mean central volume of distribution was 3.09 L and the apparent population mean peripheral volume of distribution was 5.98 L.
Elimination
The apparent population mean clearance of dulaglutide was 0.142 L/h. The elimination half-life of dulaglutide was approximately 5 days.
Metabolism – Dulaglutide is presumed to be degraded into its component amino acids by general protein catabolism pathways.
Specific Populations
The intrinsic factors of age (≥ 65 years), sex, race, ethnicity, body weight, or renal or hepatic impairment did not have a clinically relevant effect on the PK of dulaglutide as shown in Figure 1.
Abbreviations: AUC = area under the time-concentration curve; CI = confidence interval; Cmax = maximum concentration; ESRD = end-stage renal disease; PK = pharmacokinetics.
Note: Reference values for weight, age, gender, and race comparisons are 93 kg, 56 years old, male, and white, respectively; reference groups for renal and hepatic impairment data are subjects with normal renal and hepatic function from the respective clinical pharmacology studies. The weight values shown in the plot (70 and 120 kg) are the 10th and 90th percentiles of weight in the PK population.
Figure 1: Impact of intrinsic factors on dulaglutide pharmacokinetics.
Pediatric Patients
A population pharmacokinetic analysis was conducted for dulaglutide 0.75 mg and 1.5 mg using data from 128 pediatric patients 10 years of age and older with type 2 diabetes mellitus. The AUC in pediatric patients was approximately 37% lower than that in adult patients. However, this difference was not determined to be clinically meaningful.
Patients with Renal Impairment
Dulaglutide systemic exposure was increased by 20, 28, 14 and 12% for mild, moderate, severe, and ESRD renal impairment sub-groups, respectively, compared to subjects with normal renal function. The corresponding values for increase in Cmax were 13, 23, 20 and 11%, respectively (Figure 1). Additionally, in a 52 week clinical trial in patients with type 2 diabetes mellitus and moderate to severe renal impairment, the PK behavior of TRULICITY 0.75 mg and 1.5 mg once weekly was similar to that demonstrated in previous clinical studies [see Warning and Precautions (5.5), Use in Specific Populations (8.6)].
Patients with Hepatic Impairment
Dulaglutide systemic exposure decreased by 23, 33 and 21% for mild, moderate and severe hepatic impairment groups, respectively, compared to subjects with normal hepatic function, and Cmax was decreased by a similar magnitude (Figure 1) [see Use in Specific Populations (8.7)].
Drug Interaction Studies
The potential effect of co-administered medications on the PK of dulaglutide 1.5 mg and vice versa was studied in several single- and multiple-dose studies in healthy subjects, patients with type 2 diabetes mellitus, and patients with hypertension.
Potential for Dulaglutide to Influence the Pharmacokinetics of Other Drugs
Dulaglutide slows gastric emptying and, as a result, may reduce the extent and rate of absorption of orally co-administered medications. In clinical pharmacology studies, dulaglutide at a dose of 1.5 mg did not affect the absorption of the tested orally administered medications to any clinically relevant degree. The delay in gastric emptying is dose-dependent but is attenuated with the recommended dose escalation to higher doses of TRULICITY [see Dosage and Administration (2.1), Drug Interactions (7.1)]. The delay is largest after the first dose and diminishes with subsequent doses. PK measures indicating the magnitude of these interactions are presented in Figure 2.
Abbreviations: AUC = area under the time-concentration curve; CI = confidence interval; Cmax = maximum concentration; PK = pharmacokinetics.
Note: Reference group is co-administered medication given alone.
Figure 2: Impact of dulaglutide 1.5 mg on the pharmacokinetics of co-administered medications.
Potential for Co-administered Drugs to Influence the Pharmacokinetics of Dulaglutide
In a clinical pharmacology study, the co-administration of a single dose of 1.5 mg dulaglutide with steady-state dose of 100 mg sitagliptin caused an increase in dulaglutide AUC and Cmax of approximately 38% and 27%, which is not considered clinically relevant.
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies.
In glycemic control trials in adults with type 2 diabetes mellitus (monotherapy and combination therapy) [see Clinical Studies (14.2, 14.3)], during a treatment period ranging from 24 to 104 weeks, 64/3,907 (1.6%) of TRULICITY-treated patients developed anti-dulaglutide antibodies (referred to as anti-drug-antibodies (ADA)). Of the 64 TRULICITY-treated patients that developed ADA, 34 patients (0.9% of the overall population) developed dulaglutide-neutralizing antibodies, and 36 patients (0.9% of the overall population) developed antibodies against native GLP-1. There was no identified clinically significant effect of ADA on pharmacokinetics, pharmacodynamics, safety, or effectiveness of TRULICITY over the 24 to 104 week treatment duration in the trials in adults with type 2 diabetes mellitus.
During the 26-week controlled period of the glycemic control trial in pediatric patients 10 years of age or older with type 2 diabetes mellitus [see Clinical Studies (14.6)], 4/101 (4%) of TRULICITY-treated pediatric patients developed ADA. Of the 4 pediatric patients that developed ADA, 1 patient (1% of the overall population) developed dulaglutide-neutralizing antibodies and 3 patients (3% of the overall population) developed antibodies against native GLP-1. During the 52-week postbaseline period of the same trial (through safety follow-up), 6/103 (6%) of TRULICITY-treated patients developed ADA. Of the 6 patients that developed ADA, 1 patient (1% of the overall population) developed dulaglutide-neutralizing antibodies and 4 patients (4% of the overall population) developed antibodies against native GLP-1. Because of the low occurrence of ADA, the effect of these antibodies on the pharmacokinetics, pharmacodynamics, safety, and/or effectiveness of TRULICITY is unknown in pediatric patients.
A 2-year carcinogenicity study was conducted with dulaglutide in male and female rats at doses of 0.05, 0.5, 1.5, and 5 mg/kg (0.2-, 3-, 8-, and 24-fold the MRHD of 4.5 mg once weekly based on AUC) administered by subcutaneous injection twice weekly. In rats, dulaglutide caused a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and/or carcinomas) compared to controls, at ≥3-fold the MRHD based on AUC. A statistically significant increase in C-cell adenomas was observed in rats receiving dulaglutide at ≥0.5 mg/kg. Numerical increases in thyroid C-cell carcinomas occurred at 5 mg/kg (24 times the MRHD based on AUC) and were considered to be treatment-related despite the absence of statistical significance.
A 6-month carcinogenicity study was conducted with dulaglutide in rasH2 transgenic mice at doses of 0.3, 1, and 3 mg/kg administered by subcutaneous injection twice weekly. Dulaglutide did not produce increased incidences of thyroid C-cell hyperplasia or neoplasia at any dose.
Dulaglutide is a recombinant protein; no genotoxicity studies have been conducted.
Human relevance of thyroid C-cell tumors in rats is unknown and could not be determined by clinical studies or nonclinical studies [see Boxed Warning and Warnings and Precautions (5.1)].
In fertility and early embryonic development studies in male and female rats, no adverse effects of dulaglutide on sperm morphology, mating, fertility, conception, and embryonic survival were observed at up to 16.3 mg/kg (55-fold the MRHD based on AUC). In female rats, an increase in the number of females with prolonged diestrus and a dose-related decrease in the mean number of corpora lutea, implantation sites, and viable embryos were observed at ≥4.9 mg/kg (≥13-fold the MRHD based on AUC), which occurred in the presence of decreased maternal food consumption and body weight gain.
Zucker diabetic fatty (ZDF) rats were given 0.5, 1.5, or 5 mg/kg/twice weekly of dulaglutide (1-, 3-, and 13-fold the MRHD based on AUC) for 3 months. Increases of 12% to 33% in total and pancreatic amylase, but not lipase, were observed at all doses without microscopic pancreatic inflammatory correlates in individual animals. Other changes in the dulaglutide-treated animals included increased interlobular ductal epithelium without active ductal cell proliferation (≥0.5 mg/kg), increased acinar atrophy with/without inflammation (≥1.5 mg/kg), and increased neutrophilic inflammation of the acinar pancreas (5 mg/kg).
Treatment of monkeys for 12 months with 8.15 mg/kg/twice weekly of dulaglutide (nearly 200-fold the MRHD based on AUC) demonstrated no evidence of pancreatic inflammation or pancreatic intraepithelial neoplasia. In 4 of 19 monkeys on dulaglutide treatment, there was an increase in goblet cells within the pancreatic ducts, but no differences from the control group in total amylase or lipase at study termination. There were no proliferative changes in the thyroid C-cells.
TRULICITY has been studied in adults as monotherapy and in combination with metformin, sulfonylurea, metformin and sulfonylurea, metformin and thiazolidinedione, sodium-glucose co-transporter-2 inhibitors (SGLT2i) with or without metformin, basal insulin with or without metformin, and prandial insulin with or without metformin. TRULICITY has also been studied in patients with type 2 diabetes mellitus and moderate to severe renal impairment.
Dose escalation was performed in one trial in adults with TRULICITY doses up to 4.5 mg added to metformin. All other clinical studies in adults evaluated TRULICITY 0.75 mg and 1.5 mg without dose escalation; patients were initiated and maintained on either 0.75 mg or 1.5 mg for the duration of the trials [see Clinical Studies (14.2, 14.3, 14.4)].
TRULICITY 0.75 mg and 1.5 mg was studied in pediatric patients 10 years of age and older with type 2 diabetes in combination with or without metformin and/or basal insulin treatment [see Clinical Studies (14.6)].
In patients with type 2 diabetes mellitus, TRULICITY produced reductions from baseline in HbA1c compared to placebo. No overall differences in glycemic effectiveness were observed across demographic subgroups (age, gender, race/ethnicity, duration of diabetes).
A cardiovascular outcomes trial was conducted in adult patients with type 2 diabetes mellitus and established cardiovascular (CV) disease or multiple cardiovascular risk factors. Patients were randomized to TRULICITY 1.5 mg or placebo both added to standard of care. TRULICITY significantly reduced the risk of first occurrence of primary composite endpoint of CV death, non-fatal MI, or non-fatal stroke [see Clinical Studies (14.5)].
In a double-blind trial with primary endpoint at 26 weeks, 807 adult patients inadequately treated with diet and exercise, or with diet and exercise and one antidiabetic agent used at submaximal dose, were randomized to TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or metformin 1500 to 2000 mg/day following a two-week washout. Seventy-five percent (75%) of the randomized population were treated with one antidiabetic agent at the screening visit. Most patients previously treated with an antidiabetic agent were receiving metformin (~90%) at a median dose of 1000 mg daily and approximately 10% were receiving a sulfonylurea.
Patients had a mean age of 56 years and a mean duration of type 2 diabetes of 3 years. Forty-four percent were male. The White, Black and Asian race accounted for 74%, 7% and 8% of the population, respectively. Twenty-nine percent of the trial population were from the US.
Treatment with TRULICITY 0.75 mg and 1.5 mg once weekly resulted in reduction in HbA1c from baseline at 26-weeks (Table 4). The difference in observed effect size between TRULICITY 0.75 mg and 1.5 mg, respectively, and metformin excluded the pre-specified non-inferiority margin of 0.4%.
| |||
| |||
| |||
| |||
| 26-Week Primary Time Point | |||
| TRULICITY 0.75 mg | TRULICITY 1.5 mg | Metformin 1500-2000 mg | |
| Intent-to-Treat (ITT) Population (N)‡ | 270 | 269 | 268 |
| HbA1c (%) (Mean) | |||
| Baseline | 7.6 | 7.6 | 7.6 |
| Change from baselineb | -0.7 | -0.8 | -0.6 |
| Fasting Serum Glucose (mg/dL) (Mean) | |||
| Baseline | 161 | 164 | 161 |
| Change from baselineb | -26 | -29 | -24 |
| Body Weight (kg) (Mean) | |||
| Baseline | 91.8 | 92.7 | 92.4 |
| Change from baselineb | -1.4 | -2.3 | -2.2 |
Sitagliptin-Controlled Trial (Add-on to Metformin)
In this placebo-controlled, double-blind trial with primary endpoint at 52 weeks, 972 adult patients were randomized to placebo, TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or sitagliptin 100 mg/day (after 26 weeks, patients in the placebo treatment group received blinded sitagliptin 100 mg/day for the remainder of the trial), all as add-on to metformin. Randomization occurred after an 11-week lead-in period to allow for a metformin titration period, followed by a 6-week glycemic stabilization period. Patients had a mean age of 54 years; mean duration of type 2 diabetes of 7 years; 48% were male; race: White, Black and Asian were 53%, 4% and 27%, respectively; and 24% of the trial population were in the US.
At the 26-week placebo-controlled time point, the HbA1c change was 0.1%, -1.0%, -1.2%, and -0.6% for placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and sitagliptin, respectively. The percentage of patients who achieved HbA1c <7.0% was 22%, 56%, 62% and 39% for placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and sitagliptin, respectively. At 26 weeks, there was a mean weight reduction of 1.4 kg, 2.7 kg, 3.0 kg, and 1.4 kg for placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and sitagliptin, respectively. There was a mean reduction of fasting glucose of 9 mg/dL, 35 mg/dL, 41 mg/dL, and 18 mg/dL for placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and sitagliptin, respectively.
Treatment with TRULICITY 0.75 mg and 1.5 mg once weekly resulted in a statistically significant reduction in HbA1c compared to placebo (at 26 weeks) and compared to sitagliptin (at 26 and 52 weeks), all in combination with metformin (Table 5 and Figure 3).
| |||
| |||
| |||
| |||
| |||
| |||
| 52-Week Primary Time Point | |||
| TRULICITY 0.75 mg | TRULICITY 1.5 mg | Sitagliptin 100 mg | |
| Intent-to-Treat (ITT) Population (N)‡ | 281 | 279 | 273 |
| HbA1c (%) (Mean) | |||
| Baseline | 8.2 | 8.1 | 8.0 |
| Change from baselineb | -0.9 | -1.1 | -0.4 |
| Difference from sitagliptinb (95% CI) | -0.5 (-0.7, -0.3)†† | -0.7 (-0.9, -0.5)†† | - |
| Percentage of patients HbA1c <7.0% | 49## | 59## | 33 |
| Fasting Plasma Glucose (mg/dL) (Mean) | |||
| Baseline | 174 | 173 | 171 |
| Change from baselineb | -30 | -41 | -14 |
| Difference from sitagliptinb (95% CI) | -15 (-22, -9) | -27 (-33, -20) | - |
| Body Weight (kg) (Mean) | |||
| Baseline | 85.5 | 86.5 | 85.8 |
| Change from baselineb | -2.7 | -3.1 | -1.5 |
| Difference from sitagliptinb (95% CI) | -1.2 (-1.8, -0.6) | -1.5 (-2.1, -0.9) | - |
| |||
| Number of patients with observed data | |||
| Placebo | 139 | 108 | |
| TRULICITY 0.75 mg | 281 | 258 | 238 |
| TRULICITY 1.5 mg | 279 | 249 | 225 |
| Sitagliptin | 273 | 241 | 219 |
Figure 3: Adjusted Mean HbA1c at each Time Point (ITT, MMRM) and at Week 52 (ITT, LOCF) in Adult Patients with Type 2 Diabetes Mellitus
Dosage Ranging Trial of TRULICITY 1.5, 3 mg, and 4.5 mg (Add-on to Metformin)
In this parallel-arm, double-blind trial with primary endpoint at 36 weeks, a total of 1842 adult patients were randomized 1:1:1 to TRULICITY 1.5 mg, TRULICITY 3 mg, or TRULICITY 4.5 mg once weekly, all as add-on to metformin (NCT03495102).
Following randomization, all patients received TRULICITY 0.75 mg once weekly. The dose was increased every 4 weeks to the next higher dose until the patients reached their assigned dose (1.5 mg, 3 mg, or 4.5 mg). Patients were to remain on the assigned study dose for the duration of the trial.
Patients had a mean age of 57.1 years; a mean duration of type 2 diabetes of 7.6 years; 51.2% were male; race: White, Black, and Asian were 85.8%, 4.5%, and 2.4%, respectively; and 27.6% of the trial population was in the US.
At 36 weeks, treatment with TRULICITY 4.5 mg resulted in a statistically significant reduction in HbA1c and in body weight compared to TRULICITY 1.5 mg (Table 6 and Figure 4).
| |||
| |||
| |||
| |||
| |||
| |||
| 36-Week Primary Time Point | |||
| TRULICITY 1.5 mg | TRULICITY 3 mg | TRULICITY 4.5 mg | |
| Intent-to-Treat (ITT) Population (N) | 612 | 616 | 614 |
| HbA1c (%) (Mean) | |||
| Baseline | 8.6 | 8.6 | 8.6 |
| Change from baselineb | -1.5 | -1.6 | -1.8 |
| Difference from 1.5 mgb (95% CI) | -0.1 (-0.2, 0.0) | -0.2 (-0.4, -0.1) ^ | |
| Percentage of patients HbA1c <7.0% c | 50 | 56 | 62 |
| Fasting Serum Glucose (mg/dL) (Mean) | |||
| Baseline | 185 | 184 | 183 |
| Change from baselineb | -45 | -46 | -51 |
| Difference from 1.5 mgb (95% CI) | - 2 (-7, 3) | -6 (-11, -2) | |
| Body Weight (kg) (Mean) | |||
| Baseline | 95.5 | 96.3 | 95.4 |
| Change from baselineb | -3.0 | -3.8 | -4.6 |
| Difference from 1.5 mgb (95% CI) | -0.9 (-1.4, -0.4) | -1.6 (-2.2, -1.1) ^^ | |
| Number of patients with observed data | |||
| TRULICITY 1.5 mg | 612 | 567 | |
| TRULICITY 3 mg | 616 | 572 | |
| TRULICITY 4.5 mg | 614 | 575 | |
Observed mean HbA1c at scheduled visits and retrieved dropout multiple imputation (MI) based estimate at week 36.
Figure 4: Mean HbA1c at each Time Point (ITT) and at Week 36 (ITT, MI)
Placebo-Controlled Trial (Add-on to Sulfonylurea)
In this 24-week placebo-controlled, double-blind trial, 299 adult patients were randomized to and received placebo or once weekly TRULICITY 1.5 mg, both as add-on to glimepiride. Patients had a mean age of 58 years; mean duration of type 2 diabetes of 8 years; 44% were male; race: White, Black, and Asian were 83%, 4%, and 2%, respectively; and 24% of the trial population were in the US.
At 24 weeks, treatment with once weekly TRULICITY 1.5 mg resulted in a statistically significant reduction in HbA1c compared to placebo (Table 7).
| ||
| ||
| ||
| ||
| ||
| 24-Week Primary Time Point | ||
| Placebo | TRULICITY 1.5 mg | |
| Intent-to-Treat (ITT) Population (N) | 60 | 239 |
| HbA1c (%) (Mean) | ||
| Baseline | 8.4 | 8.4 |
| Change from baselineb | -0.3 | -1.3 |
| Difference from placebob (95% CI) | -1.1 (-1.4, -0.7)†† | |
| Percentage of patients HbA1c <7.0%c | 17 | 50†† |
| Fasting Serum Glucose (mg/dL) (Mean) | ||
| Baseline | 175 | 178 |
| Change from baselineb | 2 | -28 |
| Difference from placebob (95% CI) | -30 (-44, -15)†† | |
| Body Weight (kg) (Mean) | ||
| Baseline | 89.5 | 84.5 |
| Change from baselineb | -0.2 | -0.5 |
| Difference from placebob (95% CI) | -0.4 (-1.2, 0.5) | |
Placebo- and Exenatide-Controlled Trial (Add-on to Metformin and Thiazolidinedione)
In this placebo-controlled trial with primary endpoint at 26 weeks, 976 adult patients were randomized to and received placebo, TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or exenatide 10 mcg BID, all as add-on to maximally tolerated doses of metformin (≥1500 mg per day) and pioglitazone (up to 45 mg per day). Exenatide treatment group assignment was open-label while the treatment assignments to placebo, TRULICITY 0.75 mg, and TRULICITY 1.5 mg were blinded. After 26 weeks, patients in the placebo treatment group were randomized to either TRULICITY 0.75 mg once weekly or TRULICITY 1.5 mg once weekly to maintain blinding. Randomization occurred after a 12-week lead-in period; during the initial 4 weeks of the lead-in period, patients were titrated to maximally tolerated doses of metformin and pioglitazone; this was followed by an 8-week glycemic stabilization period prior to randomization. Patients randomized to exenatide started at a dose of 5 mcg BID for 4 weeks and then were escalated to 10 mcg BID. Patients had a mean age of 56 years; mean duration of type 2 diabetes of 9 years; 58% were male; race: White, Black and Asian were 74%, 8% and 3%, respectively; and 81% of the trial population were in the US.
Treatment with TRULICITY 0.75 mg and 1.5 mg once weekly resulted in a statistically significant reduction in HbA1c compared to placebo (at 26 weeks) and compared to exenatide at 26 weeks (Table 8 and Figure 5). Over the 52-week trial period, the percentage of patients who required glycemic rescue was 8.9% in the TRULICITY 0.75 mg once weekly + metformin and pioglitazone treatment group, 3.2% in the TRULICITY 1.5 mg once weekly + metformin and pioglitazone treatment group, and 8.7% in the exenatide BID + metformin and pioglitazone treatment group.
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| 26-Week Primary Time Point | ||||
| Placebo | TRULICITY 0.75 mg | TRULICITY 1.5 mg | Exenatide 10 mcg BID | |
| Intent-to-Treat (ITT) Population (N)‡ | 141 | 280 | 279 | 276 |
| HbA1c (%) (Mean) | ||||
| Baseline | 8.1 | 8.1 | 8.1 | 8.1 |
| Change from baselineb | -0.5 | -1.3 | -1.5 | -1.0 |
| Difference from placebob (95% CI) | - | -0.8 (-1.0, -0.7)‡‡ | -1.1 (-1.2, -0.9)‡‡ | - |
| Difference from exenatideb (95% CI) | - | -0.3 (-0.4, -0.2)†† | -0.5 (-0.7, -0.4)†† | - |
| Percentage of patients HbA1c <7.0% | 43 | 66**, ## | 78**, ## | 52 |
| Fasting Serum Glucose (mg/dL) (Mean) | ||||
| Baseline | 166 | 159 | 162 | 164 |
| Change from baselineb | -5 | -34 | -42 | -24 |
| Difference from placebob (95% CI) | - | -30 (-36, -23) | -38 (-45, -31) | - |
| Difference from exenatideb (95% CI) | - | -10 (-15, -5) | -18 (-24, -13) | - |
| Body Weight (kg) (Mean) | ||||
| Baseline | 94.1 | 95.5 | 96.2 | 97.4 |
| Change from baselineb | 1.2 | 0.2 | -1.3 | -1.1 |
| Difference from placebob (95% CI) | - | -1.0 (-1.8, -0.3) | -2.5 (-3.3, -1.8) | - |
| Difference from exenatideb (95% CI) | - | 1.3 (0.6, 1.9) | -0.2 (-0.9, 0.4) | - |
| |||
| Number of patients with observed data | |||
| Placebo | 141 | 108 | |
| TRULICITY 0.75 mg | 280 | 251 | |
| TRULICITY 1.5 mg | 279 | 259 | |
| Exenatide | 276 | 242 | |
Figure 5: Adjusted Mean HbA1c at Each Time Point (ITT, MMRM) and at Week 26 (ITT, LOCF)
Placebo-Controlled Trial (Add-on to SGLT2i, with or without Metformin)
In this 24-week placebo-controlled, double-blind trial, 423 adult patients were randomized to and received TRULICITY 0.75 mg, TRULICITY 1.5 mg, or placebo, as add-on to sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy (96% with and 4% without metformin). Trulicity was administered once weekly, and SGLT2i was administered according to the local country label. Patients had a mean age of 57 years; mean duration of type 2 diabetes of 9.4 years; 50% were male; race: White, Black, and Asian were 89%, 3%, and 0.2%, respectively; and 21% of the trial population was in the US.
At 24 weeks, treatment with once weekly TRULICITY 0.75 mg and 1.5 mg resulted in a statistically significant reduction from baseline in HbA1c compared to placebo (Table 9).
The mean baseline body weight was 90.5, 91.1, and 92.9 kg in the placebo, TRULICITY 0.75 mg, and TRULICITY 1.5 mg groups, respectively. The mean changes from baseline in body weight at Week 24 were -2.0, -2.5, and -2.9 kg for placebo, TRULICITY 0.75 mg, and TRULICITY 1.5 mg, respectively. The difference from placebo (95% CI) was -0.9 kg (-1.7, -0.1) for TRULICITY 1.5 mg.
| |||
| |||
| |||
| |||
| |||
| 24-Week Primary Time Point | |||
| Placebo | TRULICITY 0.75 mg | TRULICITY 1.5 mg | |
| Intent-to-Treat (ITT) Population (N) | 140 | 141 | 142 |
| HbA1c (%) (Mean) | |||
| Baseline | 8.1 | 8.1 | 8.0 |
| Change from baselineb | -0.6 | -1.2 | -1.3 |
| Difference from placebob (95% CI) | - | -0.7 (-0.8, -0.5)†† | -0.8 (-0.9, -0.6)†† |
| Percentage of patients HbA1c <7.0%c | 31 | 59†† | 67†† |
| Fasting Serum Glucose (mg/dL) (Mean) | |||
| Baseline | 153 | 162 | 161 |
| Change from baselineb | -6 | -25 | -30 |
| Difference from placebob (95% CI) | - | -19 (-25, -13) | -24 (-30, -18)†† |
Insulin Glargine Controlled Trial (Add-on to Metformin and Sulfonylurea)
In this open-label comparator trial (double-blind with respect to TRULICITY dose assignment) with primary endpoint at 52 weeks, 807 adult patients were randomized to and received TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or insulin glargine once daily, all as add-on to maximally tolerated doses of metformin and glimepiride. Randomization occurred after a 10-week lead-in period; during the initial 2 weeks of the lead-in period, patients were titrated to maximally tolerated doses of metformin and glimepiride. This was followed by a 6- to 8-week glycemic stabilization period prior to randomization.
Patients randomized to insulin glargine were started on a dose of 10 units once daily. Insulin glargine dose adjustments occurred twice weekly for the first 4 weeks of treatment based on self-measured fasting plasma glucose (FPG), followed by once weekly titration through Week 8 of treatment, utilizing an algorithm that targeted a fasting plasma glucose of <100 mg/dL. Only 24% of patients were titrated to goal at the 52-week primary endpoint. The dose of glimepiride could be reduced or discontinued after randomization (at the discretion of the investigator) in the event of persistent hypoglycemia. The dose of glimepiride was reduced or discontinued in 28%, 32%, and 29% of patients randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg, and glargine.
Patients had a mean age of 57 years; mean duration of type 2 diabetes of 9 years; 51% were male; race: White, Black and Asian were 71%, 1% and 17%, respectively; and 0% of the trial population were in the US.
Treatment with TRULICITY once weekly resulted in a reduction in HbA1c from baseline at 52 weeks when used in combination with metformin and sulfonylurea (Table 10). The difference in observed effect size between TRULICITY 0.75 mg and 1.5 mg, respectively, and glargine in this trial excluded the pre-specified non-inferiority margin of 0.4%.
| |||
| |||
| |||
| |||
| 52-Week Primary Time Point | |||
| TRULICITY 0.75 mg | TRULICITY 1.5 mg | Insulin Glargine | |
| Intent-to-Treat (ITT) Population (N)‡ | 272 | 273 | 262 |
| HbA1c (%) (Mean) | |||
| Baseline | 8.1 | 8.2 | 8.1 |
| Change from baselineb | -0.8 | -1.1 | -0.6 |
| Fasting Serum Glucose (mg/dL) (Mean) | |||
| Baseline | 161 | 165 | 163 |
| Change from baselineb | -16 | -27 | -32 |
| Difference from insulin glargineb (95% CI) | 16 (9, 23) | 5 (-2, 12) | - |
| Body Weight (kg) (Mean) | |||
| Baseline | 86.4 | 85.2 | 87.6 |
| Change from baselineb | -1.3 | -1.9 | 1.4 |
| Difference from insulinb (95% CI) | -2.8 (-3.4, -2.2) | -3.3 (-3.9, -2.7) | - |
Placebo-Controlled Trial (Add-on to Basal Insulin, with or without Metformin)
In this 28-week placebo-controlled, double-blind trial, 300 adult patients were randomized to placebo or once weekly TRULICITY 1.5 mg, as add-on to titrated basal insulin glargine (with or without metformin). Patients had a mean age of 60 years; mean duration of type 2 diabetes of 13 years; 58% were male; race: White, Black, and Asian were 94%, 4%, and 0.3%, respectively; and 20% of the trial population was in the US.
The mean starting dose of insulin glargine was 37 units/day for patients receiving placebo and 41 units/day for patients receiving TRULICITY 1.5 mg. At randomization, the initial insulin glargine dose in patients with HbA1c <8.0% was reduced by 20%.
At 28 weeks, treatment with once weekly TRULICITY 1.5 mg resulted in a statistically significant reduction in HbA1c compared to placebo (Table 11).
| ||
| ||
| ||
| ||
| ||
| ||
| 28-Week Primary Time Point | ||
| Placebo | TRULICITY 1.5 mg | |
| Intent-to-Treat (ITT) Population (N) | 150 | 150 |
| HbA1c (%) (Mean) | ||
| Baseline | 8.3 | 8.4 |
| Change from baselineb | -0.7 | -1.4 |
| Difference from placebob (95% CI) | -0.7 (-0.9, -0.5)†† | |
| Percentage of patients HbA1c <7.0%c | 33 | 67†† |
| Fasting Serum Glucose (mg/dL) (Mean) | ||
| Baseline | 156 | 157 |
| Change from baselineb | -30 | -44 |
| Difference from placebob (95% CI) | -14 (-23, -4)† | |
| Body Weight (kg) (Mean) | ||
| Baseline | 92.6 | 93.3 |
| Change from baselineb | 0.8 | -1.3 |
| Difference from placebob (95% CI) | -2.1 (-2.9, -1.4)†† | |
Insulin Glargine-Controlled Trial (Combination with Prandial Insulin, with or without Metformin)
In this open-label comparator trial (double-blind with respect to TRULICITY dose assignment) with primary endpoint at 26 weeks, 884 adult patients on 1 or 2 insulin injections per day were enrolled. Randomization occurred after a 9-week lead-in period; during the initial 2 weeks of the lead-in period, patients continued their pre-trial insulin regimen but could be initiated and/or up-titrated on metformin, based on investigator discretion; this was followed by a 7-week glycemic stabilization period prior to randomization.
At randomization, patients discontinued their pre-trial insulin regimen and were randomized to TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or insulin glargine once daily, all in combination with prandial insulin lispro 3 times daily, with or without metformin. Insulin lispro was titrated in each arm based on preprandial and bedtime glucose, and insulin glargine was titrated to a fasting plasma glucose goal of <100 mg/dL. Only 36% of patients randomized to glargine were titrated to the fasting glucose goal at the 26-week primary timepoint.
Patients had a mean age of 59 years; mean duration of type 2 diabetes of 13 years; 54% were male; race: White, Black and Asian were 79%, 10% and 4%, respectively; and 33% of the trial population were in the US.
Treatment with TRULICITY 0.75 mg and 1.5 mg once weekly resulted in a reduction in HbA1c from baseline. The difference in observed effect size between TRULICITY 0.75 mg and 1.5 mg, respectively, and glargine in this trial excluded the pre-specified non-inferiority margin of 0.4% (Table 12).
| |||
| |||
| |||
| |||
| 26-Week Primary Time Point | |||
| TRULICITY 0.75 mg | TRULICITY 1.5 mg | Insulin Glargine | |
| Intent-to-Treat (ITT) Population (N)‡ | 293 | 295 | 296 |
| HbA1c (%) (Mean) | |||
| Baseline | 8.4 | 8.5 | 8.5 |
| Change from baselineb | -1.6 | -1.6 | -1.4 |
| Fasting Serum Glucose (mg/dL) (Mean) | |||
| Baseline | 150 | 157 | 154 |
| Change from baselineb | 4 | -5 | -28 |
| Difference from insulin glargineb (95% CI) | 32 (24, 41) | 24 (15, 32) | - |
| Body Weight (kg) (Mean) | |||
| Baseline | 91.7 | 91.0 | 90.8 |
| Change from baselineb | 0.2 | -0.9 | 2.3 |
| Difference from insulin glargineb (95% CI) | -2.2 (-2.8, -1.5) | -3.2 (-3.8, -2.6) | - |
In this open-label comparator trial (double-blind with respect to TRULICITY dose assignment) with primary endpoint at 26 weeks, a total of 576 adult patients with type 2 diabetes were randomized and treated to compare TRULICITY 0.75 mg and 1.5 mg with insulin glargine (NCT01621178).
Patients on insulin and other antidiabetic therapy (e.g., oral antidiabetic drugs, pramlintide) had non-insulin therapies discontinued and had their insulin dose adjusted for 12 weeks prior to randomization. Patients on insulin therapy alone maintained a stable insulin dose for 3 weeks prior to randomization. At randomization, patients discontinued their pre-trial insulin regimen and patients were randomized to TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or insulin glargine once daily, all in combination with prandial insulin lispro. For patients randomized to insulin glargine, the initial insulin glargine dose was based on the basal insulin dose prior to randomization. Insulin glargine was allowed to be titrated with a fasting plasma glucose goal of ≤150 mg/dL. Insulin lispro was allowed to be titrated with a preprandial and bedtime glucose goal of ≤180 mg/dL.
Patients had a mean age of 65 years; a mean duration of type 2 diabetes of 18 years; 52% were male; race: White, Black, and Asian were 69%, 16%, and 3%, respectively; and 32% of the trial population were in the US. At baseline, overall mean eGFR was 38 mL/min/1.73 m2, 30% of patients had eGFR <30 mL/min/1.73 m2, and 45% of patients had macroalbuminuria. Patients on over 70 units/day of basal insulin were excluded from the trial.
Treatment with TRULICITY 0.75 mg and 1.5 mg once weekly resulted in a reduction in HbA1c at 26-weeks from baseline. The difference in observed effect size between TRULICITY 0.75 mg and 1.5 mg, respectively, and glargine in this trial excluded the pre-specified non-inferiority margin of 0.4%. Mean fasting plasma glucose increased in the TRULICITY arms (Table 13).
Mean baseline body weight was 90.9 kg, 88.1 kg, and 88.2 kg in the TRULICITY 0.75 mg, TRULICITY 1.5 mg, and insulin glargine arms, respectively. The mean changes from baseline at Week 26 were -1.1, -2, and 1.9 kg in the TRULICITY 0.75 mg, TRULICITY 1.5 mg, and insulin glargine arms, respectively.
| |||
| |||
| |||
| 26-Week Primary Time Point | |||
| TRULICITY 0.75 mg | TRULICITY 1.5 mg | Insulin Glargine | |
| Intent-to-Treat Population (N) | 190 | 192 | 194 |
| HbA1c (%) (Mean) | |||
| Baseline | 8.6 | 8.6 | 8.6 |
| Change from baselineb | -0.9 | -1.0 | -1.0 |
| Difference from insulin glargineb (95% CI) | 0.0 (-0.2, 0.3) | -0.1 (-0.3, 0.2) | |
| Percentage of patients HbA1c <8.0% | 73 | 75 | 74 |
| Fasting Serum Glucose (mg/dL) (Mean) | |||
| Baseline | 167 | 161 | 170 |
| Change from baselineb | 6 | 14 | -23 |
| Difference from insulin glargineb (95% CI) | 30 (16, 43) | 37 (24, 50) | |
The REWIND trial (NCT01394952) was a multi-national, multi-center, randomized, placebo-controlled, double-blind trial. In this trial, 9901 adult patients with type 2 diabetes mellitus and established cardiovascular (CV) disease or multiple cardiovascular risk factors were randomized to TRULICITY 1.5 mg or placebo both added to standard of care. The median follow-up duration was 5.4 years. The primary endpoint was the time to the first occurrence of a composite 3-component Major Adverse Cardiovascular Events (MACE) outcome, which included CV death, non-fatal myocardial infarction (MI), and non-fatal stroke.
Patients eligible to enter the trial were 50 years of age or older who had type 2 diabetes mellitus, had an HbA1c value ≤9.5% with no lower limit at screening, and had either established CV disease, or did not have established CV disease but had multiple CV risk factors. Patients who were confirmed to have established CV disease (31.5% of randomized patients) had a history of at least one of the following: MI (16.2%); myocardial ischemia by a stress test or with cardiac imaging (9.3%); ischemic stroke (5.3%); coronary, carotid, or peripheral artery revascularization (18.0%); unstable angina (5.9%); or hospitalization for unstable angina with at least one of the following: ECG changes, myocardial ischemia on imaging, or a need for percutaneous coronary intervention (12.0%). Patients confirmed to be without established CV disease, but with multiple CV risk factors, comprised 62.8% of the randomized trial population.
At baseline, demographic and disease characteristics were balanced between treatment groups. Patients had a mean age of 66 years; 46% were female; race: White, Black, and Asian were 76%, 7%, and 4%, respectively.
The median baseline HbA1c was 7.2%. The mean duration of type 2 diabetes was 10.5 years and the mean BMI was 32.3 kg/m2.
At baseline, 50.5% of patients had mild renal impairment (eGFR ≥60 but <90 mL/min/1.73m2), 21.6% had moderate renal impairment (eGFR ≥30 but <60 mL/min/1.73m2), and 1.1% of patients had severe renal impairment (eGFR <30 mL/min/1.73m2) out of 9713 patients whose eGFR were available.
At baseline, 94.7% of patients were taking antidiabetic medication, with 10.5% of patients taking three or more antidiabetic drugs. The most common background antidiabetic drugs used at baseline were metformin (81.2%), sulfonylurea (46.0%), and insulin (23.9%). At baseline, CV disease and risk factors were managed with ACE inhibitors or angiotensin receptor blockers (81.5%), beta blockers (45.6%), calcium channel blockers (34.4%), diuretics (46.5%), statin therapy (66.1%), antithrombotic agents (58.7%), and aspirin (51.7%). During the trial, investigators were to modify anti-diabetic and cardiovascular medications to achieve local standard of care treatment targets with respect to blood glucose, lipids, and blood pressure, and manage patients recovering from an acute coronary syndrome or stroke event per local treatment guidelines.
For the primary analysis, a Cox proportional hazards model was used to test for superiority. Type I error was controlled across multiple tests. TRULICITY significantly reduced the risk of first occurrence of primary composite endpoint of CV death, non-fatal MI, or non-fatal stroke (HR: 0.88, 95% CI 0.79, 0.99). Refer to Figure 6 and Table 14.
Vital status was available for 99.7% of patients in the trial. A total of 1128 deaths were recorded during the REWIND trial. A majority of the deaths in the trial were adjudicated as CV deaths, and non-CV deaths were comparable between the treatment groups (4.4% in patients treated with TRULICITY and 5.0% in patients treated with placebo). There were 536 all-cause deaths (10.8%) in the dulaglutide group compared to 592 deaths (12.0%) in the placebo group.
| Number of patients at risk | ||||||||
| Placebo | 4952 | 4791 | 4625 | 4437 | 4275 | 3575 | 742 | |
| Dulaglutide | 4949 | 4815 | 4670 | 4521 | 4369 | 3686 | 741 | |
Figure 6. KAPLAN MEIER CURVE: Time to First Occurrence of MACE in the REWIND Trial
| |||
| |||
| |||
| |||
| |||
| Time to First Occurrence of: | TRULICITY N=4949 | Placebo N=4952 | Hazard Ratio (95% CI)b |
| Composite of non-fatal myocardial infarction, non-fatal stroke, cardiovascular death (MACE)d | 594 (12.0%) | 663 (13.4%) | 0.88 (0.79, 0.99)c |
| Cardiovascular deathd,e | 317 (6.4%) | 346 (7.0%) | 0.91 (0.78, 1.06) |
| Non-fatal myocardial infarctiond,e | 205 (4.1%) | 212 (4.3%) | 0.96 (0.79, 1.16) |
| Non-fatal stroked,e | 135 (2.7%) | 175 (3.5%) | 0.76 (0.61, 0.95) |
| Fatal or non-fatal myocardial infarctiond,e | 223 (4.5%) | 231 (4.7%) | 0.96 (0.79, 1.15) |
| Fatal or non-fatal stroked,e | 158 (3.2%) | 205 (4.1%) | 0.76 (0.62, 0.94) |
In this 26-week randomized, double-blind, placebo-controlled, parallel-arm, multicenter trial with an open-label extension for an additional 26 weeks,154 pediatric patients 10 years of age and older with type 2 diabetes mellitus, who had inadequate glycemic control despite diet and exercise, were randomized to subcutaneous TRULICITY once weekly (0.75 mg and 1.5 mg) or subcutaneous placebo once weekly in combination with or without metformin and/or basal insulin treatment (NCT02963766).
Overall, in this trial demographic and baseline disease characteristics were comparable across the treatment groups. At baseline, 71% of patients were female, and the mean age was 14.5 years (ranging from 10 to 17 years). Overall, 55% were White, 15% were Black or African American, 12% were Asian, 10% were American Indian or Alaska Native, 5% were other races, and 3% had unknown race. Additionally, 55% were Hispanic or Latino, 42% were not Hispanic or Latino, and 3% had unknown ethnicity. At baseline, the mean duration of type 2 diabetes mellitus was 2 years, mean HbA1c was 8.1%, mean weight was 90.5 kg and mean BMI was 34.1 kg/m2.
In this trial, once weekly TRULICITY (0.75 mg and 1.5 mg, pooled) (with or without metformin and/or basal insulin) was superior to placebo (p<0.001) in the change from baseline at Week 26 in HbA1c in pediatric patients 10 years of age and older with type 2 diabetes mellitus (see Table 15).
| ||||
| ||||
| ||||
| ||||
| ||||
| Placebo | TRULICITY 0.75 mg once weekly | TRULICITY 1.5 mg once weekly | TRULICITY once weekly Pooleda | |
| Intent-to-Treat Population (N) | 51 | 51 | 52 | 103 |
| HbA1c (%) (Mean)c | ||||
| Baseline Change from baseline at Week 26b Difference from placebo (95% CI)b | 8.1 0.6 - | 7.9 -0.6 -1.2 (-1.8, -0.6) | 8.2 -0.9 -1.5 (-2.1, -0.9) | 8.0 -0.8 -1.4 (-1.9, -0.8) |
| Percentage of Patients with HbA1c <7.0% at Week 26d | 14% | 55% | 48% | 52% |
| Fasting Blood Glucose (mg/dL) (Mean)c | ||||
| Baseline Change from baseline at Week 26b Difference from placebo (95% CI)b | 159 17.1 - | 149 -12.8 -29.9 (-50.7, -9.1) | 163 -24.9 -42.0 (-63.0, -20.9) | 156 -18.9 -35.9 (-54.2, -17.6) |
TRULICITY (dulaglutide) injection is a clear and colorless solution supplied in single-dose pens. TRULICITY is packaged in a cardboard outer carton containing 4 single-dose TRULICITY pens and is supplied as follows:
| Total Strength per Total Volume | NDC |
| 0.75 mg/0.5 mL | NDC 0002-1433-80 |
| 1.5 mg/0.5 mL | NDC 0002-1434-80 |
| 3 mg/0.5 mL | NDC 0002-2236-80 |
| 4.5 mg/0.5 mL | NDC 0002-3182-80 |
Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
Eli Lilly and Company, Indianapolis, IN 46285, USA
US License Number 1891
Copyright © 2014, 2026, Eli Lilly and Company. All rights reserved.
Pat.: www.lilly.com/patents
TRU-0021-USPI-20260312
|
| |||||||
| ||||||||
| Medication Guide TRULICITY® (TRU-li-si-tee) (dulaglutide) injection, for subcutaneous use | ||||||||
| Read this Medication Guide before you start using TRULICITY and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. | ||||||||
What is the most important information I should know about TRULICITY?
| ||||||||
What is TRULICITY?
| ||||||||
Do not use TRULICITY if:
| ||||||||
Before using TRULICITY, tell your healthcare provider about all of your medical conditions, including if you:
| ||||||||
| Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. TRULICITY may affect the way some medicines work, and some medicines may affect the way TRULICITY works. Before using TRULICITY, talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking other medicines to treat diabetes, including insulin or sulfonylureas. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. | ||||||||
How should I use TRULICITY?
| ||||||||
What are the possible side effects of TRULICITY?
| ||||||||
| The most common side effects of TRULICITY may include: | ||||||||
|
| |||||||
| Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of TRULICITY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. | ||||||||
| General information about the safe and effective use of TRULICITY. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TRULICITY for a condition for which it was not prescribed. Do not give TRULICITY to other people, even if they have the same symptoms you have. It may harm them. This Medication Guide summarizes the most important information about TRULICITY. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about TRULICITY that is written for health professionals. | ||||||||
| What are the ingredients in TRULICITY? Active ingredient: dulaglutide Inactive ingredients: citric acid anhydrous, mannitol, polysorbate 80, trisodium citrate dihydrate, in water for injection TRULICITY® is a registered trademark of Eli Lilly and Company. Manufactured by: Eli Lilly and Company, Indianapolis, IN 46285, USA, US License Number 1891 www.TRULICITY.com.Copyright © 2014, 2026, Eli Lilly and Company. All rights reserved. For more information, go to www.TRULICITY.com or call 1-800-545-5979.
| ||||||||
| Instructions for Use | ||
| TRULICITY® (TRU-li-si-tee) (dulaglutide) injection, for subcutaneous use 0.75 mg/0.5 mL Single-Dose Pen use 1 time each week (once weekly) | ||
 | ||
 | ||
| ||
| Information About TRULICITY Single-Dose Pen Please read this Instructions for Use and the Medication Guide carefully and completely before using your TRULICITY Single-Dose Pen. Talk to your healthcare provider about how to inject TRULICITY the right way.
| ||
| Before You Get Started | |||
|
|
|
|
| Remove | Check | Inspect | Prepare |
| Remove the Pen from the refrigerator. Leave the Base Cap on until you are ready to inject. | Check the Pen label to make sure you have the right medicine and it has not expired. | Check the Pen to make sure that it is not damaged and inspect the medicine to make sure it is not cloudy, discolored or has particles in it. | Wash your hands. |
| Choose Your Injection Site | |||
| Your healthcare provider can help you choose the injection site that is best for you. | |||
 | Change (rotate) your injection site each week. You may use the same area of your body, but be sure to choose a different injection site in that area. You may inject the medicine into your stomach (abdomen) or thigh. |
 | Another person should give you the injection in the back of your upper arm. |
| |
| Step 1 Uncap the Pen
|  |
Step 2 Place and Unlock
|  |
Step 3 Press and Hold
|  You will know your injection is complete when the gray plunger is visible. |
| Important Information Disposal of Pen Storage and Handling Commonly Asked Questions Other Information Where to Learn More | |||
Disposing of Your Used Pens
|  | ||
| Storage and Handling | |||
| |||
| Commonly Asked Questions | |||
| What if I see air bubbles in my Pen? Air bubbles are normal. What if I unlock the Pen and press the green Injection Button before pulling off the Base Cap? Do not remove the Base Cap. Throw away the Pen and get a new Pen. What if there is a drop of liquid on the tip of the needle when I remove the Base Cap? A drop of liquid on the tip of the needle is normal. Do I need to hold the Injection Button down until the injection is complete? This is not necessary, but it may help you keep the Pen steady and firm against your skin. I heard more than 2 clicks during my injection—2 louder clicks and 1 soft one. Did I get my complete injection? Some patients may hear a soft click right before the second loud click. That is the normal operation of the Pen. Do not remove the Pen from your skin until you hear the second louder click. What if there is a drop of liquid or blood on my skin after my injection? This is normal. I am not sure if my Pen worked the right way. Check to see if you have received your dose. Your dose was delivered the right way if the gray plunger is visible (see step 3). Also contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) for further instructions. Until then, store your Pen safely to avoid an accidental needle stick. | |||
| Other Information | |||
| |||
| Where to Learn More | |||
| |||
 | SCAN THIS CODE TO LAUNCH www.trulicity.com | ||
This Instructions for Use has been approved by the U.S. Food and Drug Administration. Eli Lilly and Company Indianapolis, IN 46285, USA US License Number 1891 TRULICITY is a registered trademark of Eli Lilly and Company. Copyright © 2014, 2022, Eli Lilly and Company. All rights reserved. The TRULICITY Pen meets the current dose accuracy and functional requirements of ISO 11608-1:2012 and 11608-5:2012. Revised: 11/2022 TRULOAI-0004-IFU-20221117 | |||
| Instructions for Use | ||
| TRULICITY® (TRU-li-si-tee) (dulaglutide) injection, for subcutaneous use 1.5 mg/0.5 mL Single-Dose Pen use 1 time each week (once weekly) | ||
 | ||
| ||
| ||
| Information About TRULICITY Single-Dose Pen Please read this Instructions for Use and the Medication Guide carefully and completely before using your TRULICITY Single-Dose Pen. Talk to your healthcare provider about how to inject TRULICITY the right way.
| ||
| Before You Get Started | ||||
|
|
|
| |
| Remove | Check | Inspect | Prepare | |
| Remove the Pen from the refrigerator.
Leave the Base Cap on until you are ready to inject. | Check the Pen label to make sure you have the right medicine and it has not expired. | Check the Pen to make sure that it is not damaged and inspect the medicine to make sure it is not cloudy, discolored or has particles in it. | Wash your hands. | |
| Choose Your Injection Site | ||||
| Your healthcare provider can help you choose the injection site that is best for you. | ||||
 | Change (rotate) your injection site each week. You may use the same area of your body, but be sure to choose a different injection site in that area. You may inject the medicine into your stomach (abdomen) or thigh. |
 | Another person should give you the injection in the back of your upper arm. |
 |
| Step 1 Uncap the Pen
|  |
Step 2 Place and Unlock
|  |
Step 3 Press and Hold
|  You will know your injection is complete when the gray plunger is visible. |
| Important Information Disposal of Pen Storage and Handling Commonly Asked Questions Other Information Where to Learn More | |
Disposing of Your Used Pens
|  |
| Storage and Handling |
|
| Commonly Asked Questions | ||
| What if I see air bubbles in my Pen? Air bubbles are normal. What if I unlock the Pen and press the green Injection Button before pulling off the Base Cap? Do not remove the Base Cap. Throw away the Pen and get a new Pen. What if there is a drop of liquid on the tip of the needle when I remove the Base Cap? A drop of liquid on the tip of the needle is normal. Do I need to hold the Injection Button down until the injection is complete? This is not necessary, but it may help you keep the Pen steady and firm against your skin. I heard more than 2 clicks during my injection—2 louder clicks and 1 soft one. Did I get my complete injection? Some patients may hear a soft click right before the second loud click. That is the normal operation of the Pen. Do not remove the Pen from your skin until you hear the second louder click. What if there is a drop of liquid or blood on my skin after my injection? This is normal. I am not sure if my Pen worked the right way. Check to see if you have received your dose. Your dose was delivered the right way if the gray plunger is visible (see step 3). Also contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) for further instructions. Until then, store your Pen safely to avoid an accidental needle stick. | ||
| Other Information | ||
| ||
| Where to Learn More | ||
| ||
| SCAN THIS CODE TO LAUNCH www.trulicity.com | |
| This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Eli Lilly and Company Indianapolis, IN 46285, USA US License Number 1891 TRULICITY is a registered trademark of Eli Lilly and Company. Copyright © 2014, 2022, Eli Lilly and Company. All rights reserved. The TRULICITY Pen meets the current dose accuracy and functional requirements of ISO 11608-1:2012 and 11608-5:2012. Revised: 11/2022 TRUHIAI-0004-IFU-20221117 | ||
| Instructions for Use | ||
| TRULICITY®(TRU-li-si-tee) (dulaglutide) injection, for subcutaneous use 3 mg/0.5 mL Single-Dose Pen use 1 time each week (once weekly) | ||
 | ||
| ||
|
Information About TRULICITY Single-Dose Pen
Please read this Instructions for Use and the Medication Guide carefully and completely before using your TRULICITY Single-Dose Pen. Talk to your healthcare provider about how to inject TRULICITY the right way.
Before You Get Started
|
|
|
|
| Remove | Check | Inspect | Prepare |
| Remove the Pen from the refrigerator. Leave the Base Cap on until you are ready to inject. | Check the Pen label to make sure you have the right medicine and it has not expired. Expiration Date | Check the Pen to make sure that it is not damaged and inspect the medicine to make sure it is not cloudy, discolored or has particles in it. | Wash your hands. |
Choose Your Injection Site
Your healthcare provider can help you choose the injection site that is best for you.
 | Change (rotate) your injection site each week. You may use the same area of your body, but be sure to choose a different injection site in that area. You may inject the medicine into your stomach (abdomen) or thigh. |
 | Another person should give you the injection in the back of your upper arm. |
Step 1 Uncap the Pen
|  |
Step 2 Place and Unlock
|  |
Step 3 Press and Hold
|  | |
Important Information
Disposal of Pen
Storage and Handling
Commonly Asked Questions
Other Information
Where to Learn More
Disposing of Your Used Pens
|  |
Storage and Handling
Commonly Asked Questions
What if I see air bubbles in my Pen?
Air bubbles are normal.
What if I unlock the Pen and press the green Injection Button before pulling off the Base Cap?
Do not remove the Base Cap. Throw away the Pen and get a new Pen.
What if there is a drop of liquid on the tip of the needle when I remove the Base Cap?
A drop of liquid on the tip of the needle is normal.
Do I need to hold the Injection Button down until the injection is complete?
This is not necessary, but it may help you keep the Pen steady and firm against your skin.
I heard more than 2 clicks during my injection—2 louder clicks and 1 soft one. Did I get my complete injection?
Some people may hear a soft click right before the second loud click. That is the normal operation of the Pen. Do not remove the Pen from your skin until you hear the second louder click.
What if there is a drop of liquid or blood on my skin after my injection?
This is normal.
I am not sure if my Pen worked the right way.
Check to see if you have received your dose. Your dose was delivered the right way if the gray plunger is visible (see step 3). Also contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) for further instructions. Until then, store your Pen safely to avoid an accidental needle stick.
Other Information
Where to Learn More
www.trulicity.com.
| Scan this code to launchwww.trulicity.com |
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Eli Lilly and Company
Indianapolis, IN 46285, USA
US License Number 1891
TRULICITY is a registered trademark of Eli Lilly and Company.
Copyright © 2020, 2023, Eli Lilly and Company. All rights reserved.
The TRULICITY Pen meets the current dose accuracy and functional requirements of ISO 11608-1:2012 and 11608-5:2012.
Implemented: 04/2023
TRU3MG-0002-IFU-20230407
| Instructions for Use | ||
| TRULICITY®(TRU-li-si-tee) (dulaglutide) injection, for subcutaneous use 4.5 mg/0.5 mL Single-Dose Pen use 1 time each week (once weekly)  | ||
|
Information About TRULICITY Single-Dose Pen
Please read this Instructions for Use and the Medication Guide carefully and completely before using your TRULICITY Single-Dose Pen. Talk to your healthcare provider about how to inject TRULICITY the right way.
Before You Get Started
|
|
|
|
| Remove | Check | Inspect | Prepare |
| Remove the Pen from the refrigerator. Leave the Base Cap on until you are ready to inject. | Check the Pen label to make sure you have the right medicine and it has not expired. Expiration Date | Check the Pen to make sure that it is not damaged and inspect the medicine to make sure it is not cloudy, discolored or has particles in it. | Wash your hands. |
Choose Your Injection Site
Your healthcare provider can help you choose the injection site that is best for you.
 | Change (rotate) your injection site each week. You may use the same area of your body, but be sure to choose a different injection site in that area. You may inject the medicine into your stomach (abdomen) or thigh. |
 | Another person should give you the injection in the back of your upper arm. |
Step 1 Uncap the Pen
|  | |
Step 2 Place and Unlock
|  | |
Step 3 Press and Hold
|  | ||
Important Information
Disposal of Pen
Storage and Handling
Commonly Asked Questions
Other Information
Where to Learn More
Disposing of Your Used Pens
|  |
Storage and Handling
Commonly Asked Questions
What if I see air bubbles in my Pen?
Air bubbles are normal.
What if I unlock the Pen and press the green Injection Button before pulling off the Base Cap?
Do not remove the Base Cap. Throw away the Pen and get a new Pen.
What if there is a drop of liquid on the tip of the needle when I remove the Base Cap?
A drop of liquid on the tip of the needle is normal.
Do I need to hold the Injection Button down until the injection is complete?
This is not necessary, but it may help you keep the Pen steady and firm against your skin.
I heard more than 2 clicks during my injection—2 louder clicks and 1 soft one. Did I get my complete injection?
Some people may hear a soft click right before the second loud click. That is the normal operation of the Pen. Do not remove the Pen from your skin until you hear the second louder click.
What if there is a drop of liquid or blood on my skin after my injection?
This is normal.
I am not sure if my Pen worked the right way.
Check to see if you have received your dose. Your dose was delivered the right way if the gray plunger is visible (see step 3). Also contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) for further instructions. Until then, store your Pen safely to avoid an accidental needle stick.
Other Information
Where to Learn More
www.trulicity.com.
| Scan this code to launch www.trulicity.com |
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Eli Lilly and Company
Indianapolis, IN 46285, USA
US License Number 1891
TRULICITY is a registered trademark of Eli Lilly and Company.
Copyright © 2020, 2023, Eli Lilly and Company. All rights reserved.
The TRULICITY Pen meets the current dose accuracy and functional requirements of ISO 11608-1:2012 and 11608-5:2012.
Implemented: 04/2023
TRU4.5MG-0002-IFU-20230407
NDC 0002-1433-80
4 Single-Dose Pens
Each pen delivers a 0.75 mg dose.
Use one pen every week.
Rx only
For subcutaneous use only
Single-Dose Only
Dispense the accompanying Medication Guide to each patient.
trulilcity®
(dulaglutide) injection
0.75 mg/0.5 mL
once weekly
Lilly
NDC 0002-1434-80
4 Single-Dose Pens
Each pen delivers a 1.5 mg dose.
Use one pen every week.
Rx only
For subcutaneous use only
Single-Dose Only
Dispense the accompanying Medication Guide to each patient.
trulicity®
(dulaglutide) injection
1.5 mg/0.5 mL
once weekly
Lilly
NDC 0002-2236-80
4 Single-Dose Pens
Each pen delivers a 3 mg dose.
Use one pen every week.
Rx only
For subcutaneous use only
Single-Dose Only
Dispense the accompanying Medication Guide to each patient.
trulicity®
(dulaglutide) injection
3 mg/0.5 mL
once weekly
Lilly
NDC 0002-3182-80
4 Single-Dose Pens
Each pen delivers a 4.5 mg dose.
Use one pen every week.
Rx only
For subcutaneous use only
Single-Dose Only
Dispense the accompanying Medication Guide to each patient.
trulicity®
(dulaglutide) injection
4.5 mg/0.5 mL
once weekly
Lilly
| Resource | Code type | Value | Equivalent identifiers | Source image |
|---|---|---|---|---|
| QR code link | QR Code | www.trulicity.com/ | qr-v1.jpg |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| e2db08c6-133f-4f4f-afb4-e90a2418d6f6 | Product name | 1 | 20230320 |
| ce6d5c06-3ae0-18a6-d5b3-8cd3cc0f8906 | Product name | 7 | 20210625 |
| a62a50ac-1535-4461-9768-8ae703e2e9fb | Product name | 1 | 20210525 |
| f52be47f-7aa7-46c0-b1fa-50c18dd50206 | Product name | 1 | 20201029 |
| 11ed6f83-cdd2-4637-8379-b1a1d3ae3cde | Product name | 1 | 20181101 |
| 86c45a79-b9f0-4476-a27c-6e10db098497 | Product name | 1 | 20180125 |
| d5e51f11-ad28-caa4-4b49-4143974782ad | Product name | 1 | 20150831 |
| 431af9bc-94ac-4e4b-abaa-84d1d87e74ac | Product name | 1 | 20150331 |
| 9514609b-a2a9-f8ec-6ba6-3f8e5ee89877 | Product name | 1 | 20140508 |
| bc07ef78-e82d-0c19-31f4-31f263780582 | Product name | 1 | 20140508 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0002-1433-01 | ML - Milliliter | 0002-1433 | 847fb266-84a3-41df-bfa0-5fa2023a8c74 | 1 | 2014-11-05 |
| 0002-1433-61 | ML - Milliliter | 0002-1433 | e79ca535-b831-4c92-bac7-34f92b429a4a | 1 | 2019-04-11 |
| 0002-1433-80 | ML - Milliliter | 0002-1433 | a298abfd-15a7-4fa7-9728-b1cbb53c6a6a | 1 | 2014-10-03 |
| 0002-1434-01 | ML - Milliliter | 0002-1434 | 2adb406e-8a04-4048-92dc-8ff42373e7bf | 1 | 2014-11-05 |
| 0002-1434-61 | ML - Milliliter | 0002-1434 | 29ff4373-e07c-4c99-93a4-93c18c490284 | 1 | 2026-04-20 |
| 0002-1434-80 | ML - Milliliter | 0002-1434 | 2ba45891-7fb8-415f-94e8-a4b18a13d6af | 1 | 2014-10-03 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Dulaglutide | ACTIVE INGREDIENT | WTT295HSY5 | 13 | |
| Dulaglutide | ACTIVE MOIETY | WTT295HSY5 | 13 | |
| Anhydrous Citric Acid | INACTIVE INGREDIENT | XF417D3PSL | 13 | |
| Mannitol | INACTIVE INGREDIENT | 3OWL53L36A | 13 | |
| Polysorbate 80 | INACTIVE INGREDIENT | 6OZP39ZG8H | 13 | |
| Trisodium Citrate Dihydrate | INACTIVE INGREDIENT | B22547B95K | 13 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 13 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0002-1433 | 0002-1433-01, 0002-1433-80, 0002-1433-61 |
| 0002-1434 | 0002-1434-01, 0002-1434-80, 0002-1434-61 |
| 0002-2236 | 0002-2236-01, 0002-2236-80, 0002-2236-61 |
| 0002-3182 | 0002-3182-01, 0002-3182-80, 0002-3182-61 |
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 125469 | Trulicity | dulaglutide | 351(a) | Rx | 2026-09-01 |
Every source-derived ingredient row is available through these pages.
| Version | Effective date | Source | Hydrated |
|---|---|---|---|
| 60 | 2026-03-12 | full-release | 2026-05-31 22:10:58 |
| 59 | 2025-11-18 | monthly-update | 2026-06-03 17:48:40 |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SOLUTION / INTRAMUSCULAR | 5 %w/v | ||
| Anhydrous Citric Acid | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION, SOLUTION / SUBCUTANEOUS | 25 mg | ||
| Anhydrous Citric Acid | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION, SOLUTION / SUBCUTANEOUS | 25 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SOLUTION / INTRAVENOUS | 1170 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SOLUTION / INTRAMUSCULAR | 5 %w/v | ||
| Trisodium Citrate Dihydrate | TRISODIUM CITRATE DIHYDRATE | B22547B95K | INJECTION, SOLUTION / SUBCUTANEOUS | 28 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SOLUTION / INTRAVENOUS | 1170 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.3 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SOLUTION / INTRAMUSCULAR | 5 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.3 %w/v | ||
| Mannitol | MANNITOL | 3OWL53L36A | INJECTION, SOLUTION / SUBCUTANEOUS | 99 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SOLUTION / INTRAMUSCULAR | 5 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION / SUBCUTANEOUS | 0.3 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SOLUTION / INTRAVENOUS | 1170 mg | ||
| Anhydrous Citric Acid | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION, SOLUTION / SUBCUTANEOUS | 25 mg | ||
| Mannitol | MANNITOL | 3OWL53L36A | INJECTION, SOLUTION / SUBCUTANEOUS | 99 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION / SUBCUTANEOUS | 0.3 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.3 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION / SUBCUTANEOUS | 0.3 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION / SUBCUTANEOUS | 0.3 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.3 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION / SUBCUTANEOUS | 0.3 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SOLUTION / INTRAMUSCULAR | 5 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SOLUTION / INTRAVENOUS | 1170 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION / SUBCUTANEOUS | 0.3 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SOLUTION / INTRAMUSCULAR | 5 %w/v | ||
| Trisodium Citrate Dihydrate | TRISODIUM CITRATE DIHYDRATE | B22547B95K | INJECTION, SOLUTION / SUBCUTANEOUS | 28 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SOLUTION / INTRAVENOUS | 1170 mg | ||
| Trisodium Citrate Dihydrate | TRISODIUM CITRATE DIHYDRATE | B22547B95K | INJECTION, SOLUTION / SUBCUTANEOUS | 28 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION / SUBCUTANEOUS | 0.3 %w/v | ||
| Mannitol | MANNITOL | 3OWL53L36A | INJECTION, SOLUTION / SUBCUTANEOUS | 99 mg | ||
| Mannitol | MANNITOL | 3OWL53L36A | INJECTION, SOLUTION / SUBCUTANEOUS | 99 mg | ||
| Trisodium Citrate Dihydrate | TRISODIUM CITRATE DIHYDRATE | B22547B95K | INJECTION, SOLUTION / SUBCUTANEOUS | 28 mg | ||
| Mannitol | MANNITOL | 3OWL53L36A | INJECTION, SOLUTION / SUBCUTANEOUS | 99 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION / SUBCUTANEOUS | 0.3 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SOLUTION / INTRAMUSCULAR | 5 %w/v | ||
| Trisodium Citrate Dihydrate | TRISODIUM CITRATE DIHYDRATE | B22547B95K | INJECTION, SOLUTION / SUBCUTANEOUS | 28 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SOLUTION / INTRAVENOUS | 1170 mg | ||
| Mannitol | MANNITOL | 3OWL53L36A | INJECTION, SOLUTION / SUBCUTANEOUS | 99 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SOLUTION / INTRAVENOUS | 1170 mg | ||
| Anhydrous Citric Acid | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION, SOLUTION / SUBCUTANEOUS | 25 mg | ||
| Anhydrous Citric Acid | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION, SOLUTION / SUBCUTANEOUS | 25 mg | ||
| Anhydrous Citric Acid | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION, SOLUTION / SUBCUTANEOUS | 25 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION / SUBCUTANEOUS | 0.3 %w/v | ||
| Mannitol | MANNITOL | 3OWL53L36A | INJECTION, SOLUTION / SUBCUTANEOUS | 99 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SOLUTION / INTRAVENOUS | 1170 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SOLUTION / INTRAMUSCULAR | 5 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.3 %w/v | ||
| Trisodium Citrate Dihydrate | TRISODIUM CITRATE DIHYDRATE | B22547B95K | INJECTION, SOLUTION / SUBCUTANEOUS | 28 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SOLUTION / INTRAVENOUS | 1170 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.3 %w/v | ||
| Trisodium Citrate Dihydrate | TRISODIUM CITRATE DIHYDRATE | B22547B95K | INJECTION, SOLUTION / SUBCUTANEOUS | 28 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SOLUTION / INTRAVENOUS | 1170 mg | ||
| Anhydrous Citric Acid | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION, SOLUTION / SUBCUTANEOUS | 25 mg | ||
| Mannitol | MANNITOL | 3OWL53L36A | INJECTION, SOLUTION / SUBCUTANEOUS | 99 mg | ||
| Trisodium Citrate Dihydrate | TRISODIUM CITRATE DIHYDRATE | B22547B95K | INJECTION, SOLUTION / SUBCUTANEOUS | 28 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.3 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION / SUBCUTANEOUS | 0.3 %w/v | ||
| Mannitol | MANNITOL | 3OWL53L36A | INJECTION, SOLUTION / SUBCUTANEOUS | 99 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SOLUTION / INTRAVENOUS | 1170 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Trulicity | DULAGLUTIDE | Eli Lilly and Company | 463050bd-2b1c-40f5-b3c3-0a04bb433309 | 2026-06-16 | Boxed warning, Warnings, Adverse reactions | 0002-3182-80 0002-2236-61 0002-1433-01 0002-2236-01 0002-1434-61 0002-1433-80 0002-1433-61 0002-3182-61 0002-2236-80 0002-1434-01 0002-3182-01 0002-1434-80 0002-2236 0002-3182 0002-1434 0002-1433 00002143401 00002223601 00002223661 00002318201 00002223680 00002143301 00002143480 00002318280 00002318261 00002143461 00002143361 00002143380 cfddaea0-134c-48f2-95df-3cff565e366e 463050bd-2b1c-40f5-b3c3-0a04bb433309 |
Adverse event summaries are temporarily unavailable. Other product information remains available.
